B1 Non-refereed article in a scientific journal
Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy
Authors: Marjo Nylund, Tytti Vuorinen, Laura Airas
Publisher: Elsevier
Publication year: 2020
Journal: Multiple Sclerosis and Related Disorders
Journal name in source: Multiple sclerosis and related disorders
Journal acronym: Mult Scler Relat Disord
Article number: 102058
Volume: 42
Number of pages: 3
ISSN: 2211-0348
eISSN: 2211-0356
DOI: https://doi.org/10.1016/j.msard.2020.102058
Abstract
We report here on a young woman with multiple sclerosis, who developed a condition with eosinophilia and swelling of limbs seven weeks after initiation of ocrelizumab treatment. We consider her drug reaction to be compatible with a drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome. She was treated with antihistamine and corticosteroid treatments, and recovered fully within three months of symptom onset. Ocrelizumab was not re-initiated. We are not aware of other DRESS-like cases related to ocrelizumab treatment.
We report here on a young woman with multiple sclerosis, who developed a condition with eosinophilia and swelling of limbs seven weeks after initiation of ocrelizumab treatment. We consider her drug reaction to be compatible with a drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome. She was treated with antihistamine and corticosteroid treatments, and recovered fully within three months of symptom onset. Ocrelizumab was not re-initiated. We are not aware of other DRESS-like cases related to ocrelizumab treatment.
UTU Research Portal